Group 1 - The company has decided to reappoint Beijing Dehao International Accounting Firm as the auditor for the fiscal year 2025, pending approval from the shareholders' meeting [2][12][13] - The audit fee for the current period is set at 1.2 million RMB, which includes 800,000 RMB for financial audit and 400,000 RMB for internal control audit, reflecting an increase of 200,000 RMB from the previous year [10][12] - The audit committee and board of directors have reviewed and approved the reappointment, citing the firm's diligence, independence, and professional competence [11][12][13] Group 2 - The company’s subsidiary, Yanji Pharmaceutical, has received a drug supplement application approval notice for Metronidazole and Fenbufen Capsules, allowing the transfer of the marketing authorization holder from Harbin Huari Biochemical Pharmaceutical Co., Ltd. to Yanji Pharmaceutical [38][39] - The drug is indicated for conditions such as gingivitis and periodontitis, which may enhance the company's product offerings and competitive edge in the market [41]

Core Viewpoint - Jilin Aodong Pharmaceutical Group Co., Ltd. has received approval from the National Medical Products Administration for the marketing authorization of "Metronidazole Fenbufen Capsules" through its subsidiary, Yanji Pharmaceutical [1] Group 1 - The marketing authorization holder for the drug has been changed from Harbin Huarui Biochemical Pharmaceutical Co., Ltd. to Jilin Aodong Pharmaceutical Group Yanji Co., Ltd. [1] - The drug approval number remains unchanged, indicating continuity in regulatory compliance [1] - The transfer of the drug includes the production site, formulation, production process, and quality standards, all of which remain consistent with the original product [1]

Core Viewpoint - Jilin Aodong Pharmaceutical Group Co., Ltd. has received approval from the National Medical Products Administration for the marketing authorization of "Metronidazole Fenbufen Capsules" through its subsidiary, Yanji Pharmaceutical [1] Group 1: Company Developments - The marketing authorization holder for the drug has been changed from Harbin Huarui Biochemical Pharmaceutical Co., Ltd. to Jilin Aodong Pharmaceutical Group Yanji Co., Ltd. [1] - The drug approval number remains unchanged, indicating continuity in regulatory compliance [1] Group 2: Product Details - The transfer of the drug includes the production site, formulation, production process, and quality standards, all of which remain consistent with the original product [1]